Milsaperidone

Milsaperidone
Clinical data
Trade names	Bysanti
Other names	VHX896, VHX-896
AHFS/Drugs.com	bysanti
License data	US DailyMed: Milsaperidone;
Routes of; administration	Oral
Drug class	Atypical antipsychotic
ATC code	None;
Legal status
Legal status	US: ℞-only;
Identifiers
	IUPAC name (1S)-1-[4-[3-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]propoxy]-3-methoxyphenyl]ethanol;
CAS Number	501373-88-2;
PubChem CID	10365268;
ChemSpider	8540717;
UNII	7SV1ZOG031;
KEGG	D13099;
Chemical and physical data
Formula	C24H29FN2O4
Molar mass	428.504 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H](C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC)O;
	InChI InChI=1S/C24H29FN2O4/c1-16(28)18-4-7-21(23(14-18)29-2)30-13-3-10-27-11-8-17(9-12-27)24-20-6-5-19(25)15-22(20)31-26-24/h4-7,14-17,28H,3,8-13H2,1-2H3/t16-/m0/s1; Key:SBKZGLWZGZQVHA-INIZCTEOSA-N;

Milsaperidone, sold under the brand name Bysanti, is an atypical antipsychotic used for the treatment of schizophrenia and bipolar disorder.^[1]^[2] It is a prodrug of iloperidone and acts as a dopamine D₂ receptor and serotonin 5-HT_2A receptor antagonist, among other actions.^[3]^[4] Milsaperidone was developed by Vanda Pharmaceuticals.